The increase in growth hormone production is believed to potentially enhance levels of insulin-like growth factor-1 (IGF-1), which is considered to be involved in the anabolic actions of growth hormone
and in terms of vascular barrier function, the loss of HS exposes adhesion molecules, promoting the adhesion of leukocytes and platelets, triggering inflammation and thrombosis, and further impairing renal blood supply and glomerular filtration, ultimately leading to a decrease in GFR (100)
Clinically Proven Ingredients
Importantly, inclusion on the 503A pathway would not represent FDA approval or confirmation of clinical efficacy, but rather a regulatory mechanism allowing compounding under specific conditions
Effects of Improper Storage Temperature Storing CJC-1295 and Ipamorelin outside the recommended temperature range can lead to several issues: Loss of potency : The peptide may lose its ability to stimulate growth hormone release effectively